Noozra

Two open-source tools, built with Claude, that catch expensive biology failures early — on public data, as decision-support (never a diagnosis). The off-target copilot screens a therapeutic protein against its human look-alikes before the wet lab: anti-myostatin is 89.9% identical to GDF-11, so an antibody would hit both. It finds a selective epitope (identity to GDF-11 drops 89.9%→60%), checks whether animal models will engage it, and flags developability and immunogenicity liabilities — and it retrospectively reproduces 10/10 documented antibody cross-reactions. The clinical suite re-reads old genetic reports: it re-checks variants against current ClinVar, triages missense calls, flags drug–gene mismatches (CPIC), prioritizes genes from patient phenotypes (HPO), and reads gene constraint (gnomAD). All twelve tools are driven by two Claude agents over MCP. Claude Code built the repo autonomously; five Claude agents researched the field in parallel; Claude Science ran the analyses and drew the figures. It never says "safe." 76 tests · one repo · MIT.